Medical marijuana company MGC Pharma has been granted an interim licence by the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia for its European medicinal cannabis production facility.
This approval will set MGC Pharma on a path towards the production of CannEpil, its first pharmaceutical-grade cannabis product to be used for the relief of drug-resistant epilepsy, also known as refractory epilepsy.
The interim licence is expected to be graded to full certification once the first batch of CannEpil has met some additional protocols. The company also announced that it has signed an agreement with the specialist Australian pharma distributor HL Pharma to bring CannEpil to the Australian market. Under the agreement, MGC would be responsible for securing Therapeutic Goods Administration and Office of Drug Control approval to import and supply the products in the country.
Visit: www.mgcpharma.com.au